Comparing osteoporosis treatments to improve hip bone density in postmenopausal women
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study compares two treatments for osteoporosis in postmenopausal women: a sequence of romosozumab followed by denosumab versus zoledronic acid alone. The goal is to see which approach better improves bone density in the hip. Participants will receive either the combination or the single drug for a period, and their progress will be monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman who has gone through menopause and is at least 60 years old.
- You must have osteoporosis, which means a bone density score of -2.5 or lower, or have had a broken bone after age 50.
- You must not have certain heart conditions, including a history of heart attack or stroke.
- You must not have taken certain osteoporosis medications like bisphosphonates, denosumab, or romosozumab recently.
- You must not have certain metabolic bone diseases, kidney problems, or low blood calcium or vitamin D levels that are not corrected.
- You must be willing to follow the study procedures and attend scheduled visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking two osteoporosis medicines together (romosozumab and denosumab) can help prevent more broken bones in women after menopause who have already had several fractures. It may be a good option if you have weak bones and want to lower your risk of future breaks.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
Hear when a new Osteoporosis in Post-menopausal Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.